false 0001711933 0001711933 2024-10-02 2024-10-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): October 2, 2024

 

 

 

Akoya Biosciences, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware 001-40344 47-5586242
(State or other jurisdiction
of incorporation) 		(Commission
File Number)		 (IRS Employer
Identification No.)

 

100 Campus Drive, 6th Floor

Marlborough, MA
(Address of principal executive offices)

 01752
(Zip Code)

 

(855) 896-8401

(Registrant’s telephone number, including area code)

 

 

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol		   Name of each exchange on which registered
Common stock, par value $0.00001 per share   AKYA   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company   x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ¨

 

 

 

 

 

 

Item 8.01 Other Events.

 

On October 2, 2024, Scott Mendel was appointed Chairman of the Board of Directors (the “Board”) of Akoya Biosciences, Inc., effective immediately. Mr. Mendel succeeds Robert Shepler, who will continue to serve as a member of the Board.

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: October 3, 2024 Akoya Biosciences, Inc.
     
  By:

/s/ Brian McKelligon

    Brian McKelligon
    Chief Executive Officer

 

3

v3.24.3
Cover
Oct. 02, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 02, 2024
Entity File Number 001-40344
Entity Registrant Name Akoya Biosciences, Inc.
Entity Central Index Key 0001711933
Entity Tax Identification Number 47-5586242
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 100 Campus Drive
Entity Address, Address Line Two 6th Floor
Entity Address, City or Town Marlborough
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01752
City Area Code 855
Local Phone Number 896-8401
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.00001 per share
Trading Symbol AKYA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Akoya BioSciences (NASDAQ:AKYA)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024 Haga Click aquí para más Gráficas Akoya BioSciences.
Akoya BioSciences (NASDAQ:AKYA)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024 Haga Click aquí para más Gráficas Akoya BioSciences.